These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 2153808)

  • 1. Quantitative structure-activity relationships within a series of melatonin analogs and related indolealkylamines.
    Lewis DF; Arendt J; English J
    J Pharmacol Exp Ther; 1990 Jan; 252(1):370-3. PubMed ID: 2153808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melatonin receptor ligands: synthesis of new melatonin derivatives and comprehensive comparative molecular field analysis (CoMFA) study.
    Mor M; Rivara S; Silva C; Bordi F; Plazzi PV; Spadoni G; Diamantini G; Balsamini C; Tarzia G; Fraschini F; Lucini V; Nonno R; Stankov BM
    J Med Chem; 1998 Sep; 41(20):3831-44. PubMed ID: 9748358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel quantitative structure-activity relationship method to predict the affinities of MT3 melatonin binding site.
    Du H; Wang J; Zhang X; Hu Z
    Eur J Med Chem; 2008 Dec; 43(12):2861-9. PubMed ID: 18400335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-dimensional quantitative structure-activity relationship of melatonin receptor ligands: a comparative molecular field analysis study.
    Sicsic S; Serraz I; Andrieux J; Brémont B; Mathé-Allainmat M; Poncet A; Shen S; Langlois M
    J Med Chem; 1997 Feb; 40(5):739-48. PubMed ID: 9057860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-bromoacetyl 5-methoxytryptamine: an irreversible melatonin ligand?
    Chong NW; Evans JE; Sugden D
    Biochem Biophys Res Commun; 1993 Jun; 193(3):1355-61. PubMed ID: 8391805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation.
    Rivara S; Mor M; Silva C; Zuliani V; Vacondio F; Spadoni G; Bedini A; Tarzia G; Lucini V; Pannacci M; Fraschini F; Plazzi PV
    J Med Chem; 2003 Apr; 46(8):1429-39. PubMed ID: 12672242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New naphthalenic ligands of melatoninergic receptors].
    Adam G; Guardiola-Lemaitre B; Yous S; Lesieur D; Morgan P; Howell HE; Andrieux J; Caignard DH; Pfeiffer B; Renard P
    J Pharm Belg; 1992; 47(4):374-80. PubMed ID: 1328595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reassessing the melatonin pharmacophore--enantiomeric resolution, pharmacological activity, structure analysis, and molecular modeling of a constrained chiral melatonin analogue.
    Rivara S; Diamantini G; Di Giacomo B; Lamba D; Gatti G; Lucini V; Pannacci M; Mor M; Spadoni G; Tarzia G
    Bioorg Med Chem; 2006 May; 14(10):3383-91. PubMed ID: 16431121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Theoretical study of the quantitative structure-activity relationships for the toxicity of dibenzo-p-dioxins.
    Zhao YY; Tao FM; Zeng EY
    Chemosphere; 2008 Aug; 73(1):86-91. PubMed ID: 18589475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophoric search and 3D-QSAR comparative molecular field analysis studies on agonists of melatonin sheep receptors.
    Marot C; Chavatte P; Morin-Allory L; Viaud MC; Guillaumet G; Renard P; Lesieur D; Michel A
    J Med Chem; 1998 Nov; 41(23):4453-65. PubMed ID: 9804685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bicyclic melatonin receptor agonists containing a ring-junction nitrogen: Synthesis, biological evaluation, and molecular modeling of the putative bioactive conformation.
    Elsner J; Boeckler F; Davidson K; Sugden D; Gmeiner P
    Bioorg Med Chem; 2006 Mar; 14(6):1949-58. PubMed ID: 16290939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and structure-activity relationship of novel benzoxazole derivatives as melatonin receptor agonists.
    Sun LQ; Chen J; Bruce M; Deskus JA; Epperson JR; Takaki K; Johnson G; Iben L; Mahle CD; Ryan E; Xu C
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3799-802. PubMed ID: 15203165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. All-atom models for the non-nucleoside binding site of HIV-1 reverse transcriptase complexed with inhibitors: a 3D QSAR approach.
    Gussio R; Pattabiraman N; Zaharevitz DW; Kellogg GE; Topol IA; Rice WG; Schaeffer CA; Erickson JW; Burt SK
    J Med Chem; 1996 Apr; 39(8):1645-50. PubMed ID: 8648604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides.
    Garratt PJ; Travard S; Vonhoff S; Tsotinis A; Sugden D
    J Med Chem; 1996 Apr; 39(9):1797-805. PubMed ID: 8627603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformationally restrained melatonin analogues: synthesis, binding affinity for the melatonin receptor, evaluation of the biological activity, and molecular modeling study.
    Spadoni G; Balsamini C; Diamantini G; Di Giacomo B; Tarzia G; Mor M; Plazzi PV; Rivara S; Lucini V; Nonno R; Pannacci M; Fraschini F; Stankov BM
    J Med Chem; 1997 Jun; 40(13):1990-2002. PubMed ID: 9207940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor site topographies for phencyclidine-like and sigma drugs: predictions from quantitative conformational, electrostatic potential, and radioreceptor analyses.
    Manallack DT; Wong MG; Costa M; Andrews PR; Beart PM
    Mol Pharmacol; 1988 Dec; 34(6):863-79. PubMed ID: 2849051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronobiotic activity of N-[2-(2,7-dimethoxyfluoren-9-yl)ethyl]-propanamide. Synthesis and melatonergic pharmacology of fluoren-9-ylethyl amides.
    Epperson JR; Bruce MA; Catt JD; Deskus JA; Hodges DB; Karageorge GN; Keavy DJ; Mahle CD; Mattson RJ; Ortiz AA; Parker MF; Takaki KS; Watson BT; Joseph P Yevich
    Bioorg Med Chem; 2004 Sep; 12(17):4601-11. PubMed ID: 15358287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models.
    Rivara S; Lorenzi S; Mor M; Plazzi PV; Spadoni G; Bedini A; Tarzia G
    J Med Chem; 2005 Jun; 48(12):4049-60. PubMed ID: 15943478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand binding to the human MT2 melatonin receptor: the role of residues in transmembrane domains 3, 6, and 7.
    Mazna P; Berka K; Jelinkova I; Balik A; Svoboda P; Obsilova V; Obsil T; Teisinger J
    Biochem Biophys Res Commun; 2005 Jul; 332(3):726-34. PubMed ID: 15913560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping the melatonin receptor. 5. Melatonin agonists and antagonists derived from tetrahydrocyclopent[b]indoles, tetrahydrocarbazoles and hexahydrocyclohept[b]indoles.
    Davies DJ; Garratt PJ; Tocher DA; Vonhoff S; Davies J; Teh MT; Sugden D
    J Med Chem; 1998 Feb; 41(4):451-67. PubMed ID: 9484496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.